05:45 AM EDT, 05/21/2024 (MT Newswires) -- (Updates with the stock move in the headline and the second paragraph.)

Larimar Therapeutics ( LRMR ) said late Monday the US Food and Drug Administration lifted a partial clinical hold previously imposed on the clinical program to study nomlabofusp for treating Friedreich's Ataxia, an inherited nervous system disorder.

Shares of the company surged more than 17% in Tuesday's premarket activity.

Following a review of data from Larimar Therapeutics' ( LRMR ) recent four-week Phase 2 dose exploration study, the FDA lifted the hold, the company said.

Nomlabofusp is a recombinant fusion protein that will deliver human frataxin into the mitochondria of patients with Friedreich's Ataxia.

Price: 8.52, Change: +1.25, Percent Change: +17.19